AKBA News and Press, Akebia Therapeutics Inc. From 08/25/23

Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights PR Newswire Akebia to host conference call on August 25, 2023 at 9:00 a.m. ET Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult p...

2023-08-24 11:21:09 ET More on Akebia Akebia: 'Hold' Through Regulatory And Financial Hurdles Akebia Therapeutics: Take Profits Before Second Quarter Report Akebia Therapeutics: Buy This Undervalued Stock At Just 77% Of Revenue Akebia plans to resubmit vadadu...

2023-08-24 10:15:14 ET More on Akebia Akebia: 'Hold' Through Regulatory And Financial Hurdles Akebia Therapeutics: Take Profits Before Second Quarter Report Akebia Therapeutics: Buy This Undervalued Stock At Just 77% Of Revenue Akebia settles last patent laws...

Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 PR Newswire Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. , Aug. 24, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA),...

Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights PR Newswire Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass. , Aug. 23, 2023 /PRNewswire/ -- Akebia Therapeu...

2023-08-20 08:15:00 ET Related stocks stories: Compare metrics for NVDA to LOW, PTON, WDAY Nvidia continues run as Wall Street continues to praise ahead of Q2 results Nvidia: Don't Be The Greatest Fool Nvidia: 'Supercycle' Era Awaits, I'm Not Running This Tim...

Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023 PR Newswire Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing CAMBRIDGE, Mass. , Aug. 17, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. ...

2023-08-10 18:12:40 ET Akebia Therapeutics ( NASDAQ: AKBA ) said it will delay filing of its Q2 financial results due to accounting errors relating to recording and reporting of return reserves for Auryxia. However, the biopharma said that it is still on track to resubmit an N...

Akebia Therapeutics Provides Update on Form 10-Q Filing PR Newswire Akebia announces late filing of its second quarter earnings and Form 10-Q Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million Akebia believes its cash resources as of Ju...

2023-08-02 19:00:48 ET Summary Akebia Therapeutics plans to resubmit its FDA application for kidney disease drug vadadustat by Q3 2023, following initial rejection over safety concerns. Despite a decrease in revenues and a net loss in Q1 2023, Akebia's stock has seen significant g...